Kinetics of disappearance of resistance mutations and reappearance of wild-type during structured treatment interruptions

被引:25
作者
Halfon, P
Durant, J
Clevenbergh, P
Carsenti, H
Celis, L
Khiri, H
De Smet, K
De Brauwer, A
Hulstaert, F
Dellamonica, P
机构
[1] Innogenet NV, B-9052 Ghent, Belgium
[2] Lab Alphabio, Marseille, France
[3] Hop Archet, Nice, France
关键词
HIV-1; line probe assay; structured treatment interruption; HIV drug resistance/resistance mutations;
D O I
10.1097/00002030-200306130-00009
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: To monitor the disappearance of resistance-associated mutations and reappearance of wild-type (WT) virus during structured treatment interruptions (STI) using DNA sequencing and line probe assay. Methods: Eleven HIV-1-infected patients participating in the MUTAVIR study undergoing a 3-month STI after multi-HAART failure were monitored biweekly. Genotypes were assessed by sequencing and VERSANT(R) HIV-1 Resistance Assays (LiPA). Results: At treatment interruption, 54 mutations in total were identified with both methods among the patients. UPA provided a result for 93.3% of the codons at baseline. For 37 mutations, a complete reversion of mutant to WT was observed with one of the two methods. Among these, UPA detected mutations in 23 codons for 7 to 52 days longer, in 10 codons for the same period, and in four codons for a shorter time than sequencing. Similarly, UPA detected 35 WT codons 8 to 86 days earlier, and 15 at the same time point as sequencing. A sharp reduction in the number of mutations was observed at the time of viral load increase in five of the 11 patients. Taking only the codons detected by UPA into consideration, two patients showed a complete reversion to WT according to both genotyping assays at the end of the STI period. Conclusions: The determination of the timepoint at which a virus population of an HIV-1 patient undergoing STI reverts to WT is dependent on the assay used. The viral load increase in most patients is compatible with the outgrowth of virus with fewer or no mutations. (C) 2003 Lippincott Williams Wilkins.
引用
收藏
页码:1351 / 1361
页数:11
相关论文
共 23 条
[1]  
AMIEL C, 2001, 1 IAS C
[2]   HIV POPULATION-DYNAMICS IN-VIVO - IMPLICATIONS FOR GENETIC-VARIATION, PATHOGENESIS, AND THERAPY [J].
COFFIN, JM .
SCIENCE, 1995, 267 (5197) :483-489
[3]   Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. [J].
Deeks, SG ;
Wrin, T ;
Liegler, T ;
Hoh, R ;
Hayden, M ;
Barbour, JD ;
Hellmann, NS ;
Petropoulos, CJ ;
McCune, JM ;
Hellerstein, MK ;
Grant, RM .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (07) :472-480
[4]  
DESMET KAL, 2000, ANTIVIR THER S, V5, P80
[5]  
Devereux HL, 1999, AIDS, V13, pF123, DOI 10.1097/00002030-199912240-00001
[6]   Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study [J].
Egger, M ;
Hirschel, B ;
Francioli, P ;
Sudre, P ;
Wirz, M ;
Flepp, M ;
Rickenbach, M ;
Malinverni, R ;
Vernazza, P ;
Battegay, M ;
Bernasconi, E ;
Burgisser, P ;
Erb, P ;
Fierz, W ;
Grob, P ;
Gruninger, U ;
Jeannerod, L ;
Ledergerber, B ;
Luthy, R ;
Matter, L ;
Opravil, M ;
Paccaud, F ;
Perrin, L ;
Pichler, W ;
Piffaretti, GC ;
Rutschmann, O ;
Zanetti, G .
BMJ-BRITISH MEDICAL JOURNAL, 1997, 315 (7117) :1194-1199
[7]   Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy [J].
Finzi, D ;
Blankson, J ;
Siliciano, JD ;
Margolick, JB ;
Chadwick, K ;
Pierson, T ;
Smith, K ;
Lisziewicz, J ;
Lori, F ;
Flexner, C ;
Quinn, TC ;
Chaisson, RE ;
Rosenberg, E ;
Walker, B ;
Gange, S ;
Gallant, J ;
Siliciano, RF .
NATURE MEDICINE, 1999, 5 (05) :512-517
[8]   Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy [J].
García, F ;
Plana, M ;
Vidal, C ;
Cruceta, A ;
O'Brien, WA ;
Pantaleo, G ;
Pumarola, T ;
Gallart, T ;
Miró, JM ;
Gatell, JM .
AIDS, 1999, 13 (11) :F79-F86
[9]   Comparative performance of high-density oligonucleotide sequencing and dideoxynucleotide sequencing of HIV type 1 pol from clinical samples [J].
Günthard, HF ;
Wong, JK ;
Ignacio, CC ;
Havlir, DV ;
Richman, DD .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1998, 14 (10) :869-876
[10]  
HANCE A, 2000, ANTIVIR THER S, V5, P93